Tau silencing by siRNA in the P301S mouse model of tauopathy

Current Gene Therapy

Volumn 14, Issue 5, 2014, Pages 343-351

  Xu, Hong ^a,b   Rösler, Thomas W ^b   Carlsson, Thomas ^c,d   de Andrade, Anderson ^b,d   Fiala, Ondrej ^d,e   Höllerhage, Matthias ^a,b,d   Oertel, Wolfgang H ^d   Goedert, Michel ^f   Aigner, Achim ^g   Höglinger, Günter U ^a,b,d  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

^e CHARLES UNIVERSITY   (Czech Republic)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

FTDP 17 tau; In vitro; In vivo; P301S MAPT transgenic mouse; RNAi; siRNA tauopathy

Indexed keywords

MESSENGER RNA; SMALL INTERFERING RNA; TAU PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; GENE SILENCING; GENE THERAPY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TAUOPATHY; WESTERN BLOTTING; ANIMAL; ANIMAL EMBRYO; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BRAIN; C57BL MOUSE; CELL CULTURE; CYTOLOGY; DISEASE MODEL; DRUG DELIVERY SYSTEM; ENZYME IMMUNOASSAY; GENETICS; METABOLISM; NERVE CELL; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; TAUOPATHIES; TRANSGENIC MOUSE;

MUS MUSCULUS;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BRAIN; CELLS, CULTURED; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; EMBRYO, MAMMALIAN; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEURONS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TAU PROTEINS; TAUOPATHIES;

EID: 84911493266     PISSN: 15665232     EISSN: 18755631     Source Type: Journal    
DOI: 10.2174/156652321405140926160602     Document Type: Article

References (38)

1. Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol 2013; 12: 609-22.
2. Iba M, Guo JL, McBride JD, Zhang B, Trojanowski JQ, Lee VM. Synthetic tau fibrils mediate transmission of neurofibrillary tangles in a transgenic mouse model of Alzheimer's-like tauopathy. J Neu-rosci 2013; 33: 1024-37.
3. Clavaguera F, Lavenir I, Falcon B, Frank S, Goedert M, Tolnay M. "Prion-like" templated misfolding in tauopathies. Brain Pathol 2013; 23: 342-9.
4. SantaCruz K. Tau Suppression in a Neurodegenerative Mouse Model Improves Memory Function. Science 2005; 309: 476-81.
5. Hochgrafe K, Sydow A, Mandelkow EM. Regulatable transgenic mouse models of Alzheimer disease: onset, reversibility and spreading of Tau pathology. FEBS J 2013; 280: 4371-81.
6. Engel T, Hernandez F, Avila J, Lucas JJ. Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J Neurosci 2006; 26: 5083-90.
7. Morris M, Hamto P, Adame A, Devidze N, Masliah E, Mucke L. Age-appropriate cognition and subtle dopamine-independent motor deficits in aged Tau knockout mice. Neurobiol Aging 2013; 34: 1523-9.
8. Carrington JC, Ambros V. Role of microRNAs in plant and animal development. Science 2003; 301: 336-8.
9. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 2010; 11: 597-610.
10. Ramachandran PS, Keiser MS, Davidson BL. Recent advances in RNA interference therapeutics for CNS diseases. Neurotherapeutics 2013; 10: 473-85.
11. Dorn, G, Patel S, Wotherspoon G, et al. siRNA relieves chronic neuropathic pain. Nucleic Acids Res 2004; 32: e49.
12. Thakker DR, Natt F, Husken D, et al. Neurochemical and behavioral consequences of widespread gene knockdown in the adult mouse brain by using nonviral RNA interference. Proc Natl Acad Sci U S A 2004; 101: 17270-5.
13. Piedrahita D, Hernandez I, Lopez-Tobon A, et al. Silencing of CDK5 reduces neurofibrillary tangles in transgenic Alzheimer's mice. J Neurosci 2010; 30: 13966-76.
14. Bellucci A, Westwood AJ, Ingram E, Casamenti F, Goedert M, Spillantini MG. Induction of inflammatory mediators and microglial activation in mice transgenic for mutant human P301S tau protein. Am J Pathol 2004; 165: 1643-52.
15. Culmsee C, Gerling N, Lehmann M, et al. Nerve growth factor survival signaling in cultured hippocampal neurons is mediated through TrkA and requires the common neurotrophin receptor P75. Neuroscience 2002; 115: 1089-108.
16. Hollerhage M, Goebel JN, de Andrade A, et al. Trifluoperazine rescues human dopaminergic cells from wild-type alpha-synuclein-induced toxicity. Neurobiol Aging 2014; 35: 1700-11.
17. Franklin KBJ, P. G., The mouse brain in stereotaxic coordinates. 2nd ed. San Diego, CA: Academic Press; 1997.
18. Sen N, Hara MR, Ahmad AS, et al. GOSPEL: a neuroprotective protein that binds to GAPDH upon S-nitrosylation. Neuron 2009; 63: 81-91.
19. Allen B, Ingram E, Takao M, et al. Abundant tau filaments and nonapoptotic neurodegeneration in transgenic mice expressing human P301S tau protein. J Neurosci 2002; 22: 9340-51.
20. Scattoni ML, Gasparini L, Alleva E, Goedert M, Calamandrei G, Spillantini MG. Early behavioural markers of disease in P301S tau transgenic mice. Behav Brain Res 2010; 208: 250-7.
21. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, Mello CC. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998; 391: 806-11.
22. Kim JW, Zhang YH, Zern MA, Rossi JJ, Wu J. Short hairpin RNA causes the methylation of transforming growth factor-beta receptor II promoter and silencing of the target gene in rat hepatic stellate cells. Biochem Biophys Res Commun 2007; 359: 292-7.
23. Raoul C, Abbas-Terki T, Bensadoun JC, et al. Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS. Nat Med 2005; 11: 423-8.
24. Aigner A. Gene silencing through RNA interference (RNAi) in vivo: strategies based on the direct application of siRNAs. J Bio-technol 2006; 124: 12-25.
25. Boudreau RL, Spengler RM, Davidson BL. Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease. Mol Ther 2011; 19: 2169-77.
26. Vandenberghe LH, Xiao R, Lock M, Lin J, Korn M, Wilson JM. Efficient serotype-dependent release of functional vector into the culture medium during adeno-associated virus manufacturing. Hum Gene Ther 2010; 21: 1251-7.
27. Anderson RD, Haskell RE, Xia H, Roessler BJ, BL Davidson. A simple method for the rapid generation of recombinant adenovirus vectors. Gene Ther 2000; 7: 1034-8.
28. Deng Y, Wang CC, Choy KW, et al. Therapeutic potentials of gene silencing by RNA interference: Principles, challenges, and new strategies. Gene 2014; 538(2): 217-27.
29. Musacchio T, Torchilin VP. siRNA delivery: from basics to therapeutic applications. Front Biosci (Landmark Ed) 2013; 18: 58-79.
30. Kumari A, Kumar V, Yadav SK. Nanocarriers: a tool to overcome biological barriers in siRNA delivery. Expert Opin Biol Ther 2011; 11: 1327-39.
31. Miller VM, Gouvion CM, Davidson BL, Paulson HL. Targeting Alzheimer's disease genes with RNA interference: an efficient strategy for silencing mutant alleles. Nucleic Acids Res 2004; 32: 661-8.
32. Grzelinski M, Urban-Klein B, Martens T, et al. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum Gene Ther 2006; 17: 751-66.
33. Lim J, Simanek EE. Triazine dendrimers as drug delivery systems: from synthesis to therapy. Adv Drug Deliv Rev 2012; 64: 826-35.
34. Gomez D, Kessler K, Michel JB, Vranckx R. Modifications of chromatin dynamics control Smad2 pathway activation in aneurysmal smooth muscle cells. Circ Res 2013; 113: 881-90.
35. Jiang S, Park DW, Stigler WS, et al. Mitochondria and AMP-activated protein kinase-dependent mechanism of efferocytosis. J Biol Chem 2013; 288: 26013-26.
36. Nakajima H, Kubo T, Semi Y, et al. A rapid, targeted, neuron-selective, in vivo knockdown following a single intracerebroven-tricular injection of a novel chemically modified siRNA in the adult rat brain. J Biotechnol 2012; 157: 326-33.
37. McCormack AL, Mak SK, Henderson JM, Bumcrot D, Farrer MJ, di Monte DA. Alpha-synuclein suppression by targeted small interfering RNA in the primate substantia nigra. PLoS One 2010; 5: e12122.
38. DeVos SL, Goncharoff DK, Chen G, et al. Antisense reduction of tau in adult mice protects against seizures. J Neurosci 2013; 33: 12887-97.